PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
16 hedge funds and large institutions have $10M invested in PLx Pharma Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
11% less funds holding
Funds holding: 18 → 16 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
28% less capital invested
Capital invested by funds: $13.9M → $10M (-$3.89M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$867K |
| 2 |
HWA
Heritage Way Advisors
Rockford,
Illinois
|
+$29.1K |
| 3 |
Renaissance Technologies
New York
|
+$23.3K |
| 4 |
Millennium Management
New York
|
+$11.9K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$8.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
Nottingham Advisors
Amherst,
New York
|
-$422K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$14.5K |
| 3 |
AG
Aperio Group
Sausalito,
California
|
-$13K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9K |
| 5 |
IWA
IBEX Wealth Advisors
Bedminster,
New Jersey
|
-$5K |
PLXP Hedge Fund Activity: Q3 2019 in Review
16 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q3 2019, worth a combined $10M — down 28% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PLXP and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $867K. The largest seller was Nottingham Advisors, exiting entirely with an estimated $422K sold.
- 16 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q3 2019, down from 18 in Q2 2019.
- Funds reported $10M of PLx Pharma Inc. Common Stock stock for Q3 2019, down 28% quarter-over-quarter.
- 3 funds opened new PLx Pharma Inc. Common Stock positions in Q3 2019 and 4 closed out, a net change of -1 holder.
- The largest PLx Pharma Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $867K added.
- The largest PLx Pharma Inc. Common Stock seller in Q3 2019 was Nottingham Advisors, an estimated $422K sold.
Based on aggregated 13F filings for Q3 2019.